It has been a mixed year for Accelevation Holdings Corp. insiders: $4.1 million bought by five people and $360 million sold by one, so more selling than buying overall.
Biggest single buyer: Rubiera Michael, CEO, with roughly $3.6 million. C-suite participation is part of the picture here.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. This quarter so far: net selling.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | OGP VIII, LLC | Director | Sell | 20,000,000 | $18.00 | $360.0M | SEC |
| Oct 5, 2026 | Donahue Paul D | Director | Buy | 7,000 | $18.00 | $126K | SEC |
| Oct 5, 2026 | JONES GINGER M | Director | Buy | 10,000 | $18.00 | $180K | SEC |
| Oct 5, 2026 | Rubiera Michael | CEO | Buy | 200,000 | $18.00 | $3.6M | SEC |
| Oct 5, 2026 | Rubiera Michael | CEO | Buy | 3,200 | $18.00 | $58K | SEC |
| Oct 5, 2026 | Jewell Brent C | COO | Buy | 2,500 | $18.00 | $45K | SEC |
| Oct 5, 2026 | HECKES HOWARD C | Director | Buy | 5,000 | $18.00 | $90K | SEC |
In the last 12 months Accelevation Holdings Corp. insiders made open-market purchases worth about $4.1 million and sales worth about $360 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ACCV was filed on 2026-10-05.
No congressional trades in ACCV were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).